Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

International Journal of Infectious Diseases

卷:110

Ali Albarrak¹  Othman Ali Alghamdi²  Salma Al Bahrani³  Meshael M. Almershad³  Fatimah H. Hakami³  Mansour Y. Alghamdi³  Arulanantham Zechariah Jebakumar³  Mesfer Abdullah Alghamdi³  Asmaa K. Al Abaadi³  Sausan A. Alkhrashi³  Mohamed Hany El Gezery³  Mansour Moklif Alenazi³  Jaffar A. Al-Tawfiq⁴ 

[1] Infectious Disease Unit, Specialty Internal Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia;

[2] Infectious Disease Division, Internal Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia;

[3] King Fahad Military Medical Complex, Dhahran, Saudi Arabia;

[4] Vice deanship of postgraduate studies and Research, Prince Sultan Military College of Health Sciences, Riyadh, Saudi Arabia;

关键词: ChAdOx1-S;    COVID-19 vaccine;    SARS-CoV-2;    Oxford-AstraZeneca vaccine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. Methods: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. Results: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. Conclusion: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period.

【 授权许可】

Unknown